Eyeworld

Contact information Name: ASCRS NEWS by Julia Donaldson ASCRS Foundation Coordinator 10 | EYEWORLD | SEPTEMBER 2019 remains an inspiration for many young doctors exploring humanitarian care for the first time. For Dr. Litwin, the 2019 award recipient, service has been a quiet, life- long undertaking. Dr. Chang explained, "Dick personifies the unsung hero— someone who neither seeks nor receives recognition for a lifetime of great deeds. Indeed, very few will have heard of this ophthalmologist in solo private practice, who's had tremendous impact on the treatment of cataract blindness in the developing world." Dr. Litwin began his service in a familiar way, as part of a high-volume cataract surgery mission trip to India in 1982. He later transitioned to providing on-the-ground physician education, then served as a key diplomat advocating internationally on behalf of humanitarian eyecare or- ganizations. Dr. Litwin's cultivation of long-term friendships and mentorships in the communities he has served has set his service apart. With these two honorees, the Chang Humanitarian Award has recog- nized both a household name and an unsung hero of humanitarian eyecare. The Foundation needs ASCRS mem- bers' assistance to identify worthy can- didates who have demonstrated a com- mitment to service and volunteerism. Members and others in the ophthalmic industry are called upon to nominate ophthalmologists doing exceptional hu- manitarian work in the fight to alleviate global blindness. Nominations will be accepted through September 15, 2019. To learn more about the ASCRS Foundation Chang Humanitarian Award and to submit a nomination, visit www.ascrsfoundation.org/ changaward. T wo years ago, a generous gift from David and Victoria Chang created the Chang Humanitarian Award, a new way to bring attention to some of the great sight givers. The goal of the award is to honor and recognize outstanding humani- tarian work with a focus on cataract blindness and disability. With its two previous honorees, Alan Crandall, MD, and Richard Litwin, MD, the Chang Humanitarian Award has established a blueprint for the caliber of philanthro- pist it will recognize. On July 15, the ASCRS Foundation opened nomina- tions for the 2020 award. As ASCRS members and others in the ophthalmic community consider who to nominate this year, it's instructive to look back at the two superstars that have been honored thus far. As Howard Fine, MD, explained at the time the inaugural Chang Hu- manitarian Award was given, "If you aspire to be the best physician possible and the best human being possible, you need look no further for a role model than Alan Crandall." Dr. Crandall has centered his career around bringing humanitarian aid to remote areas and underserved people around the world. The list of places he's served speaks volumes to his dedication: Ghana, Ethiopia, South Sudan, Tanzania, Kenya, Nepal, India, China, Guatemala, Egypt, Micronesia, Ton- ga, Rwanda, Hai- ti, and Cuba, as well as domestic efforts in Utah. Dr. Crandall's service has been recognized inter- nationally, and he Nominations open for third Chang Humanitarian Award Contact information Donaldson: jdonaldson@ascrs.org ACRYSOF ® IQ TORIC IOL IMPORTANT PRODUCT INFORMATION CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. INDICATIONS: The AcrySof ® IQ Toric posterior chamber intraocular lenses are intended for primary implantation in the capsular bag of the eye for visual correction of aphakia and pre-existing corneal astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia, who desire improved uncorrected distance vision, reduction of residual refractive cylinder and increased spectacle independence for distance vision. WARNING/PRECAUTION: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Toric IOLs should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. All viscoelastics should be removed from both the anterior and posterior sides of the lens; residual viscoelastics may allow the lens to rotate. Optical theory suggests that high astigmatic patients (i.e. > 2.5 D) may experience spatial distortions. Possible toric IOL related factors may include residual cylindrical error or axis misalignments. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof ® IQ Toric Cylinder Power IOLs. Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof ® Natural IOL and normal color vision. The effect on vision of the AcrySof ® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS ® or BSS PLUS ® Sterile Intraocular Irrigating Solutions. ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions. © 2018 Novartis 7/18 US-TOR-18-E-1605 ACRYSOF ® IQ TORIC IOL IMPORTANT PRODUCT INFORMATION CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. INDICATIONS: The AcrySof ® IQ Toric posterior chamber intraocular lenses are intended for primary implantation in the capsular bag of the eye for visual correction of aphakia and pre-existing corneal astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia, who desire improved uncorrected distance vision, reduction of residual refractive cylinder and increased spectacle independence for distance vision. WARNING/PRECAUTION: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Toric IOLs should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. All viscoelastics should be removed from both the anterior and posterior sides of the lens; residual viscoelastics may allow the lens to rotate. Optical theory suggests that high astigmatic patients (i.e. > 2.5 D) may experience spatial distortions. Possible toric IOL related factors may include residual cylindrical error or axis misalignments. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof ® IQ Toric Cylinder Power IOLs. Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof ® Natural IOL and normal color vision. The effect on vision of the AcrySof ® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS ® or BSS PLUS ® Sterile Intraocular Irrigating Solutions. ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions. © 2018 Novartis 7/18 US-TOR-18-E-1605

• Blank Page
• Blank Page (1)